Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1638, 2014, Pages

  Andersen, Anne Poder ^a   Moreira, José M A ^a   Pedersen, Stine Falsig ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glycolysis; Hypoxia; Metabolism; pH regulation; Tumour stroma

Indexed keywords

ACIDIFICATION; BIOCHEMISTRY; CANCER; CHEMOTHERAPY; FUNCTIONAL ROLE; HOMEOSTASIS; ION; METABOLISM; OXYGEN; PATHOLOGY; PH; PLASMA; TUMOR;

ION CHANNEL;

GLYCOLYSIS; HOMEOSTASIS; HUMAN; HYPOXIA; ION TRANSPORT; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PH; PH-REGULATION; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOUR STROMA;

GLYCOLYSIS; HYPOXIA; METABOLISM; PH-REGULATION; TUMOUR STROMA;

HOMEOSTASIS; HUMANS; HYDROGEN-ION CONCENTRATION; ION CHANNELS; ION TRANSPORT; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84893431027     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0098     Document Type: Review

References (144)

1. Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. Cell 144, 646-674. (doi:10.1016/j.cell.2011.02.013)
2. Parks SK, Chiche J, Pouyssegur J. 2011 pH control mechanisms of tumor survival and growth. J. Cell Physiol. 226, 299-308. (doi:10.1002/jcp.22400)
3. Boedtkjer E, Bunch L, Pedersen SF. 2012 Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr. Pharm. Des. 18, 1345-1371. (doi:10.2174/138161212799504830)
4. Prevarskaya N, Skryma R, Shuba Y. 2010 Ion channels and the hallmarks of cancer. Trends Mol. Med. 16, 107-121. (doi:10.1016/j.molmed.2010. 01.005)
5. Becchetti A. 2011 Ion channels and transporters in cancer. 1. Ion channels and cell proliferation in cancer. Am. J. Physiol. Cell Physiol. 301, C255-C265. (doi:10.1152/ajpcell.00047.2011)
6. Pedersen SF, Stock C. 2013 Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer Res. 73, 1658-1661. (doi:10.1158/0008-5472.CAN-12-4188)
7. Gray JA. 1966 Kinetics of enamel dissolution during formation of incipient caries-like lesions. Arch Oral Biol. 11, 397-422. (doi:10.1016/0003-9969(66) 90105-1)
8. Trivedi B, Danforth WH. 1966 Effect of pH on the kinetics of frog muscle phosphofructokinase. J. Biol. Chem. 241, 4110-4112.
9. Andres V, Carreras J, Cusso R. 1990 Regulation of muscle phosphofructokinase by physiological concentrations of bisphosphorylated hexoses: effect of alkalinization. Biochem. Biophys. Res. Commun. 172, 328-334. (doi:10.1016/S0006-291X(05) 80213-X)
10. Kuwata F, Suzuki N, Otsuka K, Taguchi M, Sasai Y, Wakino H, Ito M, Ebihara S, Suzuki K. 1991 Enzymatic regulation of glycolysis and gluconeogenesis in rabbit periodontal ligament under various physiological pH conditions. J. Nihon Univ. Sch. Dent. 33, 81-90. (doi:10.2334/josnusd1959.33.81)
11. Sandoval M, Burgos J, Sepulveda FV, Cid LP. 2011 Extracellular pH in restricted domains as a gating signal for ion channels involved in transepithelial transport. Biol. Pharm. Bull. 34, 803-809. (doi:10.1248/bpb.34.803)
12. Niemeyer MI, Cid LP, Pena-Munzenmayer G, Sepulveda FV. 2010 Separate gating mechanisms mediate the regulation of K2P potassium channel TASK-2 by intra-and extracellular pH. J. Biol. Chem. 285, 16 467-16 475. (doi:10.1074/jbc.O110. 000239)
13. Rooj AK, McNicholas CM, Bartoszewski R, Bebok Z, Benos DJ, Fuller CM. 2012 Glioma-specific cation conductance regulates migration and cell cycle progression. J. Biol. Chem. 287, 4053-4065. (doi:10.1074/jbc.M111.311688)
14. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL. 2006 HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 29, L941-L949. (doi:10.1152/ajplung.00528.2005)
15. + exchanger 1 by 5-(N-ethyl-Nisopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett. 295, 198-204. (doi:10.1016/j.canlet. 2010.03.001)
16. Ullah MS, Davies AJ, Halestrap AP. 2006 The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α dependent mechanism. J. Biol. Chem. 281, 9030-9037. (doi:10.1074/jbc.M511397200)
17. Hulikova A, Harris AL, Vaughan-Jones RD, Swietach P. 2013 Regulation of intracellular pH in cancer cell lines under normoxia and hypoxia. J. Cell Physiol. 228, 743-752. (doi:10.1002/jcp.24221)
18. Brahimi-Horn MC, Pouyssegur J. 2007 Oxygen, a source of life and stress. FEBS Lett. 581, 3582-3591. (doi:10.1016/j.febslet.2007.06.018)
19. Warburg O. 1956 On respiratory impairment in cancer cells. Science 124, 269-270.
20. Warburg O. 1925 Uber den Stoffwechsel der Carcinomzelle. Klin Wochenschr. 4, 534-536. (doi:10.1007/BF01726151)
21. Zu XL, Guppy M. 2004 Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313, 459-465. (doi:10.1016/j.bbrc.2003.11.136)
22. Koppenol WH, Bounds PL, Dang CV. 2011 Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337. (doi:10.1038/nrc3038)
23. Cairns RA, Harris IS, Mak TW. 2011 Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95. (doi:10.1038/nrc2981)
24. Tennant DA, Duran RV, Gottlieb E. 2010 Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277. (doi:10.1038/nrc2817)
25. Ward PS, Thompson CB. 2012 Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308. (doi:10.1016/j.ccr.2012.02.014)
26. Schulze A, Harris AL. 2012 How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364-373. (doi:10.1038/nature11706)
27. Wallace DC. 2012 Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698. (doi:10.1038/nrc3365)
28. Dang CV. 2012 Links between metabolism and cancer. Genes Dev. 26, 877-890. (doi:10.1101/gad.189365.112)
29. Cantor JR, Sabatini DM. 2012 Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881-898. (doi:10.1158/2159-8290.CD-12-0345)
30. Kroemer G, Pouyssegur J. 2008 Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482. (doi:10.1016/j.ccr.2008.05.005)
31. Icard P, Lincet H. 2012 A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 1826, 423-433.
32. DeBerardinis RJ, Cheng T. 2010 Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324. (doi:10.1038/onc.2009.358)
33. Estrela JM, Ortega A, Obrador E. 2006 Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43, 143-181. (doi:10.1080/10408360 500523878)
34. Ward PS et al. 2010 The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234. (doi:10.1016/j.ccr.2010.01.020)
35. Losman JA, Kaelin Jr WG. 2013 What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836-852. (doi:10.1101/gad.217406.113)
36. Heldin CH, Rubin K, Pietras K, Ostman A. 2004 High interstitial fluid pressure: an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806-813. (doi:10.1038/nrc1456)
37. Vaupel P. 2004 Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14, 198-206. (doi:10.1016/j.semradonc.2004.04.008)
38. Gatenby RA, Gillies RJ. 2008 A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8, 56-61. (doi:10.1038/nrc2255)
39. Harris AL. 2002 Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47. (doi:10.1038/nrc704)
40. Mueller MM, Fusenig NE. 2004 Friends or foes: bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4, 839-849. (doi:10.1038/nrc1477)
41. Dvorak HF, Senger DR, Dvorak AM. 1983 Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2, 41-73. (doi:10.1007/BF00046905)
42. Sappino AP, Skalli O, Jackson B, Schurch W, Gabbiani G. 1988 Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 41, 707-712. (doi:10.1002/ijc.2910410512)
43. Ronnov-Jessen L, Petersen OW. 1993 Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68, 696-707.
44. Kalluri R, Zeisberg M. 2006 Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401. (doi:10.1038/nrc1877)
45. Bhowmick NA, Neilson EG, Moses HL. 2004 Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337. (doi:10.1038/nature03096)
46. Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. 2009 Desmoplasia of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 7, S44-S47. (doi:10.1016/j.cgh.2009. 07.039)
47. Kees T, Egeblad M. 2011 Innate immune cells in breast cancer: from villains to heroes? J. Mammary Gland Biol. Neoplasia 16, 189-203. (doi:10.1007/s10911-011-9224-2)
48. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. 2012 The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266-4276. (doi:10.1158/1078-0432.CCR-11-3114)
49. Nieman KM et al. 2011 Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503. (doi:10.1038/nm.2492)
50. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. 2004 Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971. (doi:10.1073/pnas.0401064101)
51. Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS. 2010 Human mammary fibroblasts stimulate invasion of breast cancer cells in a threedimensional culture and increase stroma development in mouse xenografts. BMC Cancer 10, 444. (doi:10.1186/1471-2407-10-444)
52. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. 1999 Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011.
53. Pouyssegur J, Dayan F, Mazure NM. 2006 Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443. (doi:10.1038/nature04871)
54. Semenza GL. 2010 HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20, 51-56. (doi:10.1016/j.gde. 2009.10.009)
55. Semenza GL. 2012 Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207-214. (doi:10.1016/j.tips.2012.01.005)
56. Brahimi-Horn C, Pouyssegur J. 2006 The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull. Cancer 93, E73-E80.
57. Wang GL, Semenza GL. 1993 Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268, 21 513-21 518.
58. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. 2001 HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21, 3995-4004. (doi:10.1128/MCB.21.12. 3995-4004.2001)
59. Bardos JI, Ashcroft M. 2004 Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26, 262-269. (doi:10.1002/bies.20002)
60. Semenza GL. 1998 Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 8, 588-594. (doi:10.1016/S0959-437X(98)80016-6)
61. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. 2006 HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197. (doi:10.1016/j.cmet.2006.01.012)
62. Denko NC. 2008 Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705-713. (doi:10.1038/nrc2468)
63. Vaupel PW, Frinak S, Bicher HI. 1981 Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res. 41, 2008-2013.
64. + exchanger in metastasis. Nat. Rev. Cancer 5, 786-795. (doi:10.1038/nrc1713)
65. Helmlinger G, Yuan F, Dellian M, Jain RK. 1997 Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3, 177-182. (doi:10.1038/nm0297-177)
66. Zhang X, Lin Y, Gillies RJ. 2010 Tumor pH and its measurement. J. Nucl. Med. 51, 1167-1170. (doi:10.2967/jnumed.109.068981)
67. Mekhail K, Gunaratnam L, Bonicalzi ME, Lee S. 2004 HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 6, 642-647. (doi:10.1038/ncb1144)
68. Wise DR et al. 2008 Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105, 18 782-18 787. (doi:10.1073/pnas.0802915105)
69. Gatenby RA, Gillies RJ. 2004 Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899. (doi:10.1038/nrc1478)
70. Yuneva MO et al. 2012 The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-170. (doi:10.1016/j.cmet.2011.12.015)
71. Sonveaux P et al. 2008 Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942.
72. Menendez JA, Decker JP, Lupu R. 2005 In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J. Cell Biochem. 94, 1-4. (doi:10.1002/jcb.20310)
73. Putney LK, Barber DL. 2003 Na-H exchangedependent increase in intracellular pH times G2/M entry and transition. J. Biol. Chem. 278, 44 645-44 649. (doi:10.1074/jbc.M308099200)
74. Mekhail K, Rivero-Lopez L, Khacho M, Lee S. 2006 Restriction of rRNA synthesis by VHL maintains energy equilibrium under hypoxia. Cell Cycle 5, 2401-2413. (doi:10.4161/cc.5.20.3387)
75. + exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death. Pflugers Arch. 452, 249-259. (doi:10.1007/s00424-006-0044-y)
76. + exchanger NHE1: diverse roles in regulation of cellular signaling pathways controlling proliferation, motility, and survival. In Proton homeostasis in tumorigenesis and cell death processes (ed. D Lagadic-Gossmann), pp. 13-28. Kerala, India: Research Signpost.
77. + exchangers of thick ascending limbs of rat kidney: evidence from isolated membranes. J. Physiol. 506, 689-698. (doi:10.1111/j.1469-7793.1998.689bv.x)
78. + transport pathways in mouse medullary thick limb of Henle: regulation by intracellular pH. J. Gen. Physiol. 99, 435-461. (doi:10.1085/jgp. 99.3.435)
79. +-2Cl-cotransport in the heart, brain, and blood. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R1-R25. (doi:10.1152/ajpregu. 00782.2005)
80. Wykoff CC et al. 2001 Expression of the hypoxiainducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158, 1011-1019. (doi:10.1016/S0002-9440(10)64048-5)
81. 3-cotransport to cellular pH control in human breast cancer: a role for the breast cancer susceptibility locus NBCn1 (SLC4A7). Int. J. Cancer 132, 1288-1299. (doi:10.1002/ijc.27782)
82. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. 2012 Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembr. 44, 127-139. (doi:10.1007/s10863-012-9428-1)
83. + exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness. J. Cell Physiol. 214, 810-819. (doi:10.1002/jcp.21277)
84. Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, Pedersen SF. 2010 NBCn1 and NHE1 expression and activity in DeltaNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. Exp. Cell Res. 316, 2538-2553. (doi:10.1016/j.yexcr.2010.06.005)
85. 3-cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. Cancer Lett. 317, 172-183. (doi:10.1016/j.canlet.2011.11.023)
86. + exchange, motility, and invasion induced by serum deprivation. J. Biol. Chem. 275, 5361-5369. (doi:10.1074/jbc.275.8.5361)
87. Sansone P et al. 2007 IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117, 3988-4002. (doi:10.1172/JCI32533)
88. + exchange in astrocytes. J. Biol. Chem. 269, 13 811-13 816.
89. Schwartz MA, Both G, Lechene C. 1989 Effect of cell spreading on cytoplasmic pH in normal and transformed fibroblasts. Proc. Natl Acad. Sci. USA 86, 4525-4529. (doi:10.1073/pnas.86.12.4525)
90. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M, Chi J-T. 2008 The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 4, e1000293. (doi:10.1371/journal.pgen.1000293)
91. Ahmed S et al. 2009 Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41, 585-590. (doi:10.1038/ng.354)
92. Grillon E, Farion R, Fablet K, De WM, Tse CM, Donowitz M, Rémy C, Coles JA. 2011 The spatial organization of proton and lactate transport in a rat brain tumor. PLoS ONE 6, e17416. (doi:10.1371/journal.pone.0017416)
93. Meima ME, Mackley JR, Barber DL. 2007 Beyond ion translocation: structural functions of the sodium-hydrogen exchanger isoform-1. Curr. Opin. Nephrol. Hypertens. 16, 365-372. (doi:10.1097/MNH.0b013e3281bd888d)
94. + exchanger isoform 1 activation controls hexokinase II expression in benzo(a)pyrene-induced apoptosis. Cancer Res. 67, 1696-1705. (doi:10.1158/0008-5472.CAN-06-2327)
95. Hoffmann EK, Lambert IH, Pedersen SF. 2009 Physiology of cell volume regulation in vertebrates. Physiol. Rev. 89, 193-277. (doi:10.1152/physrev. 00037.2007)
96. Haas BR, Sontheimer H. 2010 Inhibition of the sodium-potassium-chloride cotransporter Isoform-1 reduces glioma invasion. Cancer Res. 70, 5597-5606. (doi:10.1158/0008-5472.CAN-09-4666)
97. Webb BA, Chimenti M, Jacobson MP, Barber DL. 2011 Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 11, 671-677. (doi:10.1038/nrc3110)
98. + channels: role in apoptosis and tumorigenesis. Pflugers Arch. 448, 261-273. (doi:10.1007/s00424-004-1255-8)
99. Trimarchi JR, Liu L, Smith PJ, Keefe DL. 2002 Apoptosis recruits two-pore domain potassium channels used for homeostatic volume regulation. Am. J. Physiol. 282, C588-C594. (doi:10.1152/ajpcell.00365.2001)
100. 2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res. 33, 1401-1408.
101. Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, Nishisho T, Sakurai T, Hiraga T. 2011 Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48, 100-105. (doi:10.1016/j.bone.2010.07.009)
102. Ramsey IS, Moran MM, Chong JA, Clapham DE. 2006 A voltage-gated proton-selective channel lacking the pore domain. Nature 440, 1213-1216. (doi:10.1038/nature04700)
103. Wang Y, Li SJ, Pan J, Che Y, Yin J, Zhao Q. 2011 Specific expression of the human voltage-gated proton channel Hv1 in highly metastatic breast cancer cells, promotes tumor progression and metastasis. Biochem. Biophys. Res. Commun. 412, 353-359. (doi:10.1016/j.bbrc.2011.07.102)
104. Wang Y, Li SJ, Wu X, Che Y, Li Q. 2012 Clinicopathological and biological significance of human voltage-gated proton channel Hv1 protein overexpression in breast cancer. J. Biol. Chem. 287, 13 877-13 888. (doi:10.1074/jbc.M112.345280)
105. Musset B, Cherny VV, Morgan D, Okamura Y, Ramsey IS, Clapham DE, DeCoursey TE. 2008 Detailed comparison of expressed and native voltage-gated proton channel currents. J. Physiol. 586, 2477-2486. (doi:10.1113/jphysiol. 2007.149427)
106. El CA, Okochi Y, Sasaki M, Arnaudeau S, Okamura Y, Demaurex N. 2010 VSOP/Hv1 proton channels sustain calcium entry, neutrophil migration, and superoxide production by limiting cell depolarization and acidification. J. Exp. Med. 207, 129-139. (doi:10.1084/jem.20091837)
107. Lu W et al. 2012 Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 10, e1001326. (doi:10.1371/journal.pbio.1001326)
108. McDermott U, Settleman J. 2009 Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J. Clin. Oncol. 27, 5650-5659. (doi:10.1200/JCO.2009. 22.9054)
109. Gonzalez-Angulo AM, Hennessy BT, Mills GB. 2010 Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783. (doi:10.1200/JCO.2009.27.0777)
110. Meric-Bernstam F, Mills GB. 2012 Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542-548. (doi:10.1038/nrclinonc.2012.127)
111. Weinstein IB. 2002 Cancer: addiction to oncogenes: the Achilles heal of cancer. Science 297, 63-64. (doi:10.1126/science.1073096)
112. Barbany G, Hoglund M, Simonsson B. 2002 Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N. Engl. J. Med. 347, 539-540. (doi:10.1056/NEJM200208153470719)
113. Druker BJ et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417. (doi:10.1056/NEJMoa062867)
114. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566. (doi:10.1038/nm0596-561)
115. Flaherty KT et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819. (doi:10.1056/NEJMoa1002011)
116. Workman P, Clarke PA. 2011 Resisting targeted therapy: fifty ways to leave your EGFR. Cancer Cell 19, 437-440. (doi:10.1016/j.ccr.2011.03.020)
117. Engelman JA et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043. (doi:10.1126/science.1141478)
118. De PM, Hanahan D. 2012 The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6, 111-127. (doi:10.1016/j.molonc. 2012.01.011)
119. Poulikakos PI et al. 2011 RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390. (doi:10.1038/nature10662)
120. Nazarian R et al. 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977. (doi:10.1038/nature09626)
121. Vousden KH, Ryan KM. 2009 p53 and metabolism. Nat. Rev. Cancer 9, 691-700. (doi:10.1038/nrc2715)
122. Dang CV. 2012 MYC on the path to cancer. Cell 149, 22-35. (doi:10.1016/j.cell.2012.03.003)
123. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. 2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329-3335. (doi:10.1073/pnas.0308061100)
124. Vander Heiden MG. 2011 Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684. (doi:10.1038/nrd3504)
125. Plathow C, Weber WA. 2008 Tumor cell metabolism imaging. J. Nucl. Med. 49(Suppl. 2), 43S-63S. (doi:10.2967/jnumed.107.045930)
126. Lordick F et al. 2007 PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8, 797-805. (doi:10.1016/S1470-2045(07)70244-9)
127. Evilevitch V et al. 2008 Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin. Cancer Res. 14, 715-720. (doi:10.1158/1078-0432.CCR-07-1762)
128. Gallamini A et al. 2007 Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746-3752. (doi:10.1200/JCO.2007. 11.6525)
129. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG. 2011 Targeting glucose metabolism: an emerging concept for anticancer therapy. Am. J. Clin. Oncol. 34, 628-635. (doi:10.1097/COC.0b013e3181e84dec)
130. Karmazyn M. 2013 NHE-1: still a viable therapeutic target. J. Mol. Cell Cardiol. 61, 77-82. (doi:10.1016/j.yjmcc.2013.02.006)
131. Mabjeesh NJ et al. 2003 2ME2 inhibits tumor growth; and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375. (doi:10.1016/S1535-6108(03)00077-1)
132. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park J-W. 2003 YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl Cancer Inst. 95, 516-525. (doi:10.1093/jnci/95.7.516)
133. Block KM et al. 2009 Direct inhibition of hypoxiainducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J. Am. Chem. Soc. 131, 18 078-18 088. (doi:10.1021/ja8062309)
134. Tan C et al. 2005 Identification of a novel smallmolecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65, 605-612.
135. Sweeney C et al. 2005 A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormonerefractory prostate cancer. Clin. Cancer Res. 11, 6625-6633. (doi:10.1158/1078-0432.CCR-05-0440)
136. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. 2007 Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25, 41-48. (doi:10.1007/s10637-006-9008-5)
137. Gerweck LE, Seetharaman K. 1996 Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56, 1194-1198.
138. Gerweck LE, Vijayappa S, Kozin S. 2006 Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5, 1275-1279. (doi:10.1158/1535-7163.MCT-06-0024)
139. Kozin SV, Shkarin P, Gerweck LE. 2001 The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 61, 4740-4743.
140. Kling J. 2012 Hypoxia-activated prodrugs forge ahead in cancer. Nat. Biotechnol. 30, 381. (doi:10.1038/nbt0512-381)
141. Ahn GO, Brown M. 2007 Targeting tumors with hypoxia-activated cytotoxins. Front. Biosci. 12, 3483-3501. (doi:10.2741/2329)
142. Weiss GJ et al. 2011 Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 17, 2997-3004. (doi:10.1158/1078-0432.CCR-10-3425)
143. Papadopoulos KP et al. 2008 A phase 1 open-label, accelerated dose-escalation study of the hypoxiaactivated prodrug AQ4N in patients with advanced malignancies. Clin. Cancer Res. 14, 7110-7115. (doi:10.1158/1078-0432.CCR-08-0483)
144. Borad MJ et al. 2013 Randomized phase II study of the efficacy and safety of gemcitabine+TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Cancer Res. 72, LB121. (doi:10.1158/1538-7445. AM2012-LB-121)